Sarepta Therapeutics Inc (SRPT)

30.73
0.68 2.20
NASDAQ : Health Care
Prev Close 31.41
Open 31.34
Day Low/High 30.56 / 31.89
52 Wk Low/High 8.00 / 41.97
Volume 2.05M
Avg Volume 2.58M
Exchange NASDAQ
Shares Outstanding 54.59M
Market Cap 1.78B
EPS -5.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Surge From Bank Earnings Doesn't Last

Surge From Bank Earnings Doesn't Last

Earnings and inauguration may be catalysts for the market.

7 Stocks Making Big Moves With Unusual Volume

7 Stocks Making Big Moves With Unusual Volume

Here's a technical look at how to trade stocks rising with unusual volume flow.

Stocks Build on Early Gains in Midday Trading, Nasdaq Moves Further into Record Territory

Stocks Build on Early Gains in Midday Trading, Nasdaq Moves Further into Record Territory

Stocks were climbing at midday on Tuesday, and the Nasdaq moved further into record territory.

Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears

Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears

Sarepta Therapeutics provides early sales numbers for its drug to treat DMD, and they topped expectations.

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.

Sarepta Therapeutics Enters Into License Agreement With Nationwide Children's Hospital For Galgt2 Gene Therapy Program

Sarepta Therapeutics Enters Into License Agreement With Nationwide Children's Hospital For Galgt2 Gene Therapy Program

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered an exclusive license agreement with Nationwide Children's Hospital, for...

Sarepta Therapeutics Enters Into Research Agreement And Option Agreement With Nationwide Children's Hospital For Microdystrophin Gene Therapy Program

Sarepta Therapeutics Enters Into Research Agreement And Option Agreement With Nationwide Children's Hospital For Microdystrophin Gene Therapy Program

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research and option agreement with Nationwide Children's Hospital on...

Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified

Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified

Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Trying to Knock Out Some Individual Trades, but it Is not Easy

Trying to Knock Out Some Individual Trades, but it Is not Easy

If the indices take out yesterday's lows I'll be very bearish very quickly.

Market Sees Rise in Performance Anxiety

Market Sees Rise in Performance Anxiety

I've got my eye on steel and biotechnology names to put cash to work.

Sarepta Therapeutics To Present Company Overview At The 2017 35th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics To Present Company Overview At The 2017 35th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the 35 th Annual J.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on December 30, 2016, that were previously approved by the Compensation Committee of...

Shark Bites: We Knew Today Would Be Slow, but Come On…

Shark Bites: We Knew Today Would Be Slow, but Come On…

Don't force it; there's no energy.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Sarepta Therapeutics Announces EMA Validation Of Eteplirsen Authorization Application For Treatment Of Duchenne Muscular Dystrophy Amenable To Exon Skipping 51

Sarepta Therapeutics Announces EMA Validation Of Eteplirsen Authorization Application For Treatment Of Duchenne Muscular Dystrophy Amenable To Exon Skipping 51

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced that the European Medicines Agency (EMA) validated the previously submitted Marketing...

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks

'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks

Alaska Air is 'among the best,' says Jim Cramer; he also likes Southwest.

Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq

Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq

How did these technology stocks suddenly get their groove back? asks Jim Cramer.

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High

The Dow Jones Industrial Average's winning streak continued after closing higher for the 18th time in 22 sessions. The S&P 500 also hit a new record high.

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally

The S&P 500 and Dow Jones Industrial Average trade at session highs early Wednesday afternoon as a broad rally overshadows a slump in health care stocks.

S&P 500 and Dow Reverse Losses to Post Intraday Records

S&P 500 and Dow Reverse Losses to Post Intraday Records

The S&P 500 reverses an earlier loss to post small gains, trading at a new intraday record, thanks to broad gains across all sectors save for health care.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on November 30, 2016, that were previously approved by the Compensation Committee of...

Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Handout

Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Handout

There is no shortage of opinions and politics as the House prepares for a vote Nov. 30 on 21st Century Cures Act.

PTC Therapeutics Duchenne Drug Wins Extended European Approval

PTC Therapeutics Duchenne Drug Wins Extended European Approval

The news that Translarna will remain on the European market for at least five more years sent PTC Therapeutics shares soaring.